Venbio Partners 13F annual report
Venbio Partners is an investment fund managing more than $351 million ran by Robert Adelman. There are currently 9 companies in Mr. Adelman’s portfolio. The largest investments include ALX Oncology and Harmony Biosciences Hldgs In, together worth $149 million.
$351 million Assets Under Management (AUM)
As of 8th August 2022, Venbio Partners’s top holding is 9,699,925 shares of ALX Oncology currently worth over $78.5 million and making up 22.3% of the portfolio value.Relative to the number of outstanding shares of ALX Oncology, Venbio Partners owns more than 0.2% of the company.In addition, the fund holds 1,448,720 shares of Harmony Biosciences Hldgs In worth $70.7 million. The third-largest holding is Ventyx Biosciences Inc worth $61.3 million and the next is Pharvaris N V worth $50.9 million, with 2,301,451 shares owned.
Currently, Venbio Partners's portfolio is worth at least $351 million. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Venbio Partners
The Venbio Partners office and employees reside in San Francisco, California. According to the last 13-F report filed with the SEC, Robert Adelman serves as the Manager at Venbio Partners.
